US multi-state operator iAnthus Capital Holdings (CSE:IAN) will pay a 30.6 percent premium per share for the merger of fellow operator MPX Bioceutical (CSE:MPX), the company announced on Thursday (October 18). 

The transaction will see an all stock merger between the two companies, combining the US presence of the new entity to 10 legal states.

MPX shareholders will gain a C$1.28 consideration per MPX share, which will get them 0.1673 common shares of iAnthus. The total value of the transaction was placed at C$835 million.

“The nascent US cannabis market is still in a land-grab phase, and we feel that our footprint when combined with iAnthus, provides our investors with the strongest possible exposure to this explosive marketplace,” Scott Boyes, CEO of MPX, said in the announcement.

Shares of MPX rocketed in early trading on Thursday following the announcement by 19.39 percent. As of 12:30 p.m. EST, to reach a price per share of C$1.17.

iAnthus also grew in value with a 5.37 percent increase for a price of C$8.05.

Closing of the transaction will require the approval of MPX shareholders. No details were immediately given on the special meeting needed for the approval.

Hadley Ford, CEO of iAnthus, said this was a “watershed” moment for the company and would double the footprint of the company in the fractured US market.

In the US, cannabis remains an illegal drug on a federal level, however, some states have gone ahead and legalized the medical and even recreational use of marijuana.

Companies are tasked with operating growing facilities, retail dispensaries, distribution networks or other assets through a multi-state view.

The combined assets from the two operators will represent 10 states permitted to operate, 56 retail locations and 14 facilities either used for cultivation or processing.

iAnthus will also gain the experience of Beth Stavola, chief operations officer of MPX, who will become chief strategy officer and director of the resulting company. Stavola led the way for MPX in its expansion this year.

The combination between the two companies will also see the creation of MPX International, a new venture which will hold all the non-US assets of the two.

This new company will seek an application to list on the Canadian Securities Exchange (CSE) according to the announcement.

MPX owns Canadian licensed producer (LP) Canveda, an acquisition which was completed as a way to manufacture and distribute cannabis oils, cannabis derivatives and cannabinoid-infused products. MPX purchased Canveda for a total purchase price of C$18.1 million.

Investor takeaway

Following a positive market reaction so far, the play for the US market gets more validation through a combination that continues the trend of mergers and acquisitions in the cannabis space seen throughout 2018.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the appointment of Mr. Al Reese, Jr., to its Board of Directors

Mr. Reese has over 40 years experience in public and private businesses including as CFO of a formerly Nasdaq-listed energy company where he arranged finance transactions totaling over $10 billion dollars during his 20-year tenure. Mr. Reese was a Director and Chairman of the Audit Committee of a community bank in Texas for ten years until such time as it was acquired by a larger banking group in 2018.

Keep reading... Show less

Mexico looks to be closer than ever to cannabis reform, with the country releasing its regulation plans to make the drug legal in medical settings.

Meanwhile, despite the financial hardships seen recently in the Canadian cannabis market, CEOs in the country are still receiving top dollar, as per a new study.

Keep reading... Show less

Not for Distribution to United States Newswire Services or for Dissemination in the United States

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today the pricing of its previously announced best efforts overnight marketed offering (the “Offering”) of subordinate voting shares (the “Offered Securities”) of the Company at a price of C$16.00 per share for a total gross proceeds of approximately US$125 Million. The issue price represents a 3.3% discount to the last close of the Company’s subordinate voting shares traded on the Canadian Securities Exchange as of January 14, 2021. 100% of the Offering is expected to be purchased by a total of seven new and existing institutional investors, including current shareholder, Wasatch Global Investors.

Keep reading... Show less

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from leaders at: Tilray, Inc. (NASDAQ: TLRY), Icanic Brands (OTC: ICNAF) (CSE: ICAN) Red Light Holland (OTC: TRUFF) (CSE: TRIP) and Aphria, Inc. (NASDAQ: APHA).

Investors are cheering new and expected legislation which is opening new market opportunities for both cannabis and psychedelics globally. Innovation in premium branding, growing technologies, manufacturing, with operational execution are key, in the drive towards profitability. Wall Street Reporter highlights the latest comments from industry thought leaders in cannabis and psychedelics:

Keep reading... Show less

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company”) today announced the closing of its previously announced underwritten public offering (the “Offering”) of 1,828,571 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a public offering price of $5.25 per unit (all prices in US$). The warrants have an exercise price of $6.58 per share, are immediately exercisable and will expire five years following the date of issuance. In connection with the Offering, the underwriter exercised in full its option to purchase an additional 274,285 shares of common stock and additional warrants to purchase 274,285 shares of common stock. The gross proceeds from the Offering were approximately $11.04 million, before deducting underwriting discounts and estimated offering expenses. No securities were offered or sold in Canada, including through the CSE or any other trading market in Canada

H.C. Wainwright & Co. (“Wainwright”) acted as the sole book-running manager for the Offering and is a non-related party to the Company.

Keep reading... Show less